KRAS and lung carcinoma: In patients with lung carcinoma, the KRAS G12C actionable mutation (AF: 24.55%, 51.46%, 21.32%, and 27.18%) was present in 4 (18.18%) patients, and the treatment options were sotorasib and bevacizumab plus chemotherapy (Tier IA).